Cases & Deals

Dendreon completes $426.9 million public offering of Common Stock

Clients Dendreon Corporation

Jones Day represented Dendreon Corporation, a biotechnology company focused on the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients, in connection with the $426.9 million public offering of Common Stock, underwritten by J.P. Morgan Securities Inc., Deutsche Bank Securities Inc., Citigroup Global Markets Inc., Lazard Capital Markets LLC, Leerink Swann LLC, Morgan Stanley & Co. Incorporated, and Needham & Company LLC.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.